A Randomized Controlled Trial of a Text Messaging Intervention to Promote Virologic Suppression and Retention in Care in an Urban Safety-Net Human Immunodeficiency Virus Clinic: The Connect4Care Trial
Overview
Authors
Affiliations
Background: Text messaging is a promising strategy to support human immunodeficiency virus (HIV) care engagement, but little is known about its efficacy in urban safety-net HIV clinics.
Methods: We conducted a randomized controlled trial of a supportive and motivational text messaging intervention, Connect4Care (C4C), among viremic patients who had a history of poor retention or were new to the clinic. Participants were randomized (stratified by new or established HIV diagnosis status) to receive either of the following for 12 months: (1) thrice-weekly intervention messages, plus texted primary care appointment reminders and a monthly text message requesting confirmation of study participation or (2) texted reminders and monthly messages alone. Viral load was assessed at 6 and 12 months. The primary outcome was virologic suppression (<200 copies/mL) at 12 months, estimated via repeated-measures log-binomial regression, adjusted for new-diagnosis status. The secondary outcome was retention in clinic care.
Results: Between August 2013 and November 2015, a total of 230 participants were randomized. Virologic suppression at 12 months was similar in intervention and control participants (48.8% vs 45.8%, respectively), yielding a rate ratio of 1.07 (95% confidence interval, .82-1.39). Suppression was higher in those with newly diagnosed infection (78.3% vs 45.3%). There were no intervention effects on the secondary outcome. Exploratory analyses suggested that patients with more responses to study text messages had better outcomes, regardless of arm.
Conclusions: The C4C text messaging intervention did not significantly increase virologic suppression or retention in care. Response to text messages may be a useful way for providers to gauge risk for poor HIV outcomes.
Clinical Trials Registration: NCT01917994.
Mehtani N, Strough A, Strieff S, Zevin B, Eveland J, Riley E J Acquir Immune Defic Syndr. 2024; 96(1):61-67.
PMID: 38346426 PMC: 11009050. DOI: 10.1097/QAI.0000000000003396.
Fonner V, Agostini T, Desai R, Hartzell P, Martin L, Meissner E AIDS Care. 2023; 36(4):452-462.
PMID: 37139535 PMC: 10622326. DOI: 10.1080/09540121.2023.2208320.
Wirtz A, Logie C, Mbuagbaw L Epidemiol Rev. 2022; 44(1):87-109.
PMID: 36124659 PMC: 10362940. DOI: 10.1093/epirev/mxac008.
Christopoulos K, Grochowski J, Mayorga-Munoz F, Hickey M, Imbert E, Szumowski J Clin Infect Dis. 2022; 76(3):e645-e651.
PMID: 35913500 PMC: 9907477. DOI: 10.1093/cid/ciac631.
Balaji D, He L, Giani S, Bosse T, Wiers R, de Bruijn G Sex Health. 2022; 19(5):391-405.
PMID: 35863761 PMC: 7613710. DOI: 10.1071/SH22016.